These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15259840)

  • 1. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
    Petersen T; Harley R; Papakostas GI; Montoya HD; Fava M; Alpert JE
    Psychol Med; 2004 Apr; 34(3):555-61. PubMed ID: 15259840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
    Perlis RH; Nierenberg AA; Alpert JE; Pava J; Matthews JD; Buchin J; Sickinger AH; Fava M
    J Clin Psychopharmacol; 2002 Oct; 22(5):474-80. PubMed ID: 12352270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Moore J; Jones JM; Foxwell AA; King J
    J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):991-8. PubMed ID: 26598474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    March J; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J;
    JAMA; 2004 Aug; 292(7):807-20. PubMed ID: 15315995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment.
    Peterson TJ; Feldman G; Harley R; Fresco DM; Graves L; Holmes A; Bogdan R; Papakostas GI; Bohn L; Lury RA; Fava M; Segal ZV
    J Consult Clin Psychol; 2007 Feb; 75(1):145-53. PubMed ID: 17295573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.
    Jarrett RB; Thase ME
    Contemp Clin Trials; 2010 Jul; 31(4):355-77. PubMed ID: 20451668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
    Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
    Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.
    Rohde P; Silva SG; Tonev ST; Kennard BD; Vitiello B; Kratochvil CJ; Reinecke MA; Curry JF; Simons AD; March JS
    Arch Gen Psychiatry; 2008 Apr; 65(4):447-55. PubMed ID: 18391133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.
    Davey CG; Chanen AM; Cotton SM; Hetrick SE; Kerr MJ; Berk M; Dean OM; Yuen K; Phelan M; Ratheesh A; Schäfer MR; Amminger GP; Parker AG; Piskulic D; Harrigan S; Mackinnon AJ; Harrison BJ; McGorry PD
    Trials; 2014 Nov; 15():425. PubMed ID: 25370185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.
    Jarrett RB; Minhajuddin A; Gershenfeld H; Friedman ES; Thase ME
    JAMA Psychiatry; 2013 Nov; 70(11):1152-60. PubMed ID: 24005123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment approaches to major depressive disorder relapse. Part 1: dose increase.
    Schmidt ME; Fava M; Zhang S; Gonzales J; Raute NJ; Judge R
    Psychother Psychosom; 2002; 71(4):190-4. PubMed ID: 12097783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder.
    Kennard BD; Emslie GJ; Mayes TL; Nightingale-Teresi J; Nakonezny PA; Hughes JL; Jones JM; Tao R; Stewart SM; Jarrett RB
    J Am Acad Child Adolesc Psychiatry; 2008 Dec; 47(12):1395-404. PubMed ID: 18978634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive-behavioral therapy added to fluoxetine in major depressive disorder after 4 weeks of fluoxetine-treatment: 16-week open label study.
    Maneeton N; Thongkam A; Maneeton B
    J Med Assoc Thai; 2010 Mar; 93(3):337-42. PubMed ID: 20420109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
    Yang H; Chuzi S; Sinicropi-Yao L; Johnson D; Chen Y; Clain A; Baer L; McGrath PJ; Stewart JW; Fava M; Papakostas GI
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):145-50. PubMed ID: 19572158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.
    Fava M; Schmidt ME; Zhang S; Gonzales J; Raute NJ; Judge R
    Psychother Psychosom; 2002; 71(4):195-9. PubMed ID: 12097784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
    Schmidt ME; Fava M; Robinson JM; Judge R
    J Clin Psychiatry; 2000 Nov; 61(11):851-7. PubMed ID: 11105738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.